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Abstract
Electrical stimulation of subthalamic nuclei (STN) is a widely used therapy in Parkinson’s disease (PD). While deep brain
stimulation (DBS) of the STN alters the neurophysiological activity in basal ganglia, the therapeutic mechanism has not
been established. A positron emission tomography (PET) study of cerebral blood flow (CBF) during speech production in
PD subjects treated with STN-DBS found significant increases in global (whole-brain) CBF.1 That study utilized a series of
whole-slice regions of interest to obtain global CBF values. The present study examined this effect using a voxel-based
principal component analysis (PCA) combined with Fisher’s linear discriminant analysis (FLDA) to classify STN-DBS on
versus STN-DBS off whole-brain images. The approach yielded wide-spread CBF changes that classified STN-DBS status
with accuracy, sensitivity, and specificity approaching 90%. The PCA component of the analysis supported the observation of a global CBF change during STN-DBS. The FLDA component demonstrated wide-spread multi-focal CBF changes.
Further, CBF measurements related to a number of subject characteristics when STN-DBS was off, but not when it was
on, suggesting that the normal relationship between CBF and behavior may be disrupted by this form of
neuromodulation.

Keywords
Deep brain stimulation, cerebral blood flow, subthalamic nucleus, Parkinson’s disease, positron emission tomography
Received 16 September 2016; Revised 16 March 2017; Accepted 20 March 2017

Introduction
High-frequency electrical stimulation of deep brain
nuclei in the basal ganglia has become a signiﬁcant
mode of neuro-modulatory therapy for movement
disorders. For Parkinson’s disease (PD), the subthalamic nucleus (STN) has been a major neurosurgical
target. Although deep brain stimulation (DBS) has
been eﬀective in controlling the levodopa-responsive
movement abnormalities in PD, the physiological
mechanisms by which this is accomplished remain
unknown.2,3 A range of possibilities have been suggested including interference with neural signals, the
desynchronization of abnormal oscillations, the alteration of inhibition and excitation within neural networks, and the modulation of neurotransmitter and
hormonal signaling.2–6 It has been recently put forward
that DBS activates astrocytes, providing a mechanism
for wide-spread eﬀects in the brain.7–9 Consistent with

this suggestion, generalized increases in cerebral
glucose metabolism10 and blood ﬂow have been
reported1 with STN-DBS. Precedents for generalized
eﬀects resulting from DBS can be found in older
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Table 1. Demographic characteristics of the subjects in the study.
ID

Age
(yrs)

PD Dur
(yrs)

Levodopa
(mg)

DBS Dur
(mos)

Left Amp
(volts)

Right Amp
(volts)

H&Y
(off)

H&Y
(on)

UPDRS III
(off)

UPDRS III
(on)

103
104
106
107
109
110
111

54
57
59
62
49
62
56

14
16
10
15
09
11
11

250
400
600
600
300
600
400

44
27
09
02
04
56
37

3.2
3.0
3.0
2.5
2.6
3.0
3.0

2.8
3.0
3.0
2.6
2.5
3.3
3.0

3.0
5.0
2.5
2.5
2.5
4.0
2.0

2.0
4.0
2.5
2.0
2.0
3.0
1.0

51.0
57.0
27.5
26.0
23.5
52.5
11.5

25.0
55.5
19.0
23.0
21.5
31.0
4.0

Note: All subjects were right-handed males and all but one subject were native speakers of English (106 was a native speaker of Italian who identified as
a native English speaker although he immigrated to the US as an adolescent). The stimulation frequency was 185 Hz, pulse width 60 ms in all cases. The
indications for STN-DBS were advanced, medically refractory PD with marked clinical swings between medication doses (i.e. on/off effects) as well as
levodopa-induced dyskinesias. Both on and off evaluations were performed at least 12 h following the last dose of levodopa, which was taken the
evening before the study. On and off studies were performed on different days separated by at least one week. Subject 104 had maximum scores on the
rigidity items on the UPDRS III, which were not responsive to DBS. Given the uncertain washout period of DBS effects, the UPDRS on-off differences
may underestimate the therapeutic effects. Key: Age is in years, duration of PD is in years, Levodopa is the daily dose, DBS duration is in months, left
and right amplitude of STN-DBS is in volts, H&Y is the Hoehn and Yahr38 functional status scale, UPDRS III is the Unified Parkinson’s Disease Rating
Scale – Motor Function.

animal studies that observed signiﬁcant changes in cerebral blood ﬂow (CBF) and blood pressure following
electrical stimulation in the region of the STN.11–15
The present study was undertaken to further explore
the characteristics of CBF changes during STN-DBS by
re-examining the images previously examined using
large regions of interest.1 A principal component analysis (PCA) was used with a Fisher’s linear discriminant
analysis (FLDA)16 to determine if a voxel-based pattern analysis could discriminate between STN-DBS on
and STN-DBS oﬀ CBF PET scans. A potential advantage of this approach is that it does not require a priori
normalization of images that are not absolutely
quantitative.

Subjects and methods
Study population
Subjects have been described previously.1 Seven, righthanded, male subjects with a mean age 57 years were
recruited from a clinical population of individuals with
PD who were being treated with bilateral STN-DBS.
Subject characteristics are presented in Table 1. All subjects provided informed consent for the speech (The
Nathan Kline Institute/Rockland Psychiatric Center
Institutional Review Board; Institutional Review
Board of the Mount Sinai School of Medicine) and
PET (Feinstein Research Institute, Northwell Health
Institutional Review Board) components of this study
in accordance with the Helsinki Declaration of 1975
(and as revised in 1983).

PET imaging
A total of 166 whole-brain CBF scans were obtained
from the seven subjects. Twelve whole-brain scans were
obtained with STN-DBS on and 12 were obtained with
STN-DBS oﬀ (one STN-DBS oﬀ session was terminated after 10 scans at the subject’s request; accordingly, for this subject, only 10 of the on scans were
used in this analysis). STN-DBS on and oﬀ PET scans
were performed on diﬀerent days, separated by at least
one week. The order of the on and oﬀ scan days was
randomized, with four subjects being scanned oﬀ ﬁrst
and three subjects being scanned on ﬁrst. All subjects
were studied at least 12 h after their last dose of levodopa, taken the prior evening. This levodopa washout
period is routinely employed in studies on the eﬀects
of DBS.17–19 All PET scans were performed at the
Feinstein Research Institute of North Shore-Long
Island Jewish Medical Center.
Subjects generally arrived at the PET suite at 8 a.m.
to be consented, interviewed, and instructed in the procedures. DBS stimulation settings were recorded. All of
the subjects were therapeutically stimulated 24 h/day,
with the average treatment duration of 25.6  21.2
months. Individual durations are listed in Table 1.
Stimulators were typically turned oﬀ at 9 a.m.
Approximately 30 min later, subjects were positioned
in the PET scanner (GE Advance Tomograph,
General Electrics) and an intraveneous line placed in
the subject’s left arm for H215O injection at 10 a.m. A
stereotactic headholder and 3D laser alignment were
used for stable and reproducible head positioning.
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Lightweight headphones were attached to the
headholder to facilitate communication with the subject. A 10-min transmission scan was performed for
attenuation correction followed by a 2D PET scan to
establish the delay time between H215O injection and
the detection of brain activity by the scanner. This was
followed by a series of 12 whole-brain 3D PET scans.
These scans were reconstructed using 3D reprojection
(3D RP) method, matrix dimensions 128  128  35,
with voxel dimensions of 2.34  2.34  4.25 mm, and
no smoothing was applied. In the DBS oﬀ studies,
stimulation was oﬀ for an average of 61 min (minimum
40 min, maximum 86 min) prior to the ﬁrst scan. The
mean total duration of scanning was 85.1  8.5 min in
the oﬀ condition and 90.9  10.8 min in the on condition. These durations were not signiﬁcantly diﬀerent.
The average inter-scan intervals for on and oﬀ conditions did not diﬀer either, at 8.3 and 7.6 min, respectively. Several intervals for scans occurring later in both
the on and oﬀ series were longer to accommodate subjects’ needs. The average dose of H215O injection for
each scan did not diﬀer in the DBS on and oﬀ conditions (on: 10.3  1.7 mCi; oﬀ: 10.7  2.1).
The scanning sequence began and ended with a resting scan. The remaining 10 scans consisted of two repetitions of ﬁve pseudorandomized speech repetition
tasks (lip closure, /pa/, /pa-ta-ka/, /pop-the-top-cop/)
and a spontaneous speech task in which subjects produced a monologue on a topic of their choice. These
tasks were produced in random order once in the ﬁrst
half of the study and repeated in reverse order in the
second half. Based on the observed brain delay time,
each speech task was initiated 15 s prior to detection of
H215O in the brain. Tasks were performed for 60 s using
the procedure reported previously.20 Blood ﬂow was
measured using a modiﬁed slow bolus injection of
H215O using an automated injection system20 and
image acquisition lasted approximately 2 min.
Following the PET study, all subjects underwent a
protocol motor speech examination. After the speech
examination, medication and STN-DBS were resumed.

Analytic method
The staﬀ involved in data acquisition were not blinded
to the DBS status. The individuals processing the data
were blinded but aware of two conditions. The analysis
was done directly on the PET images and not on parametric images of CBF. To classify STN-DBS images
(DBS on versus oﬀ condition), we used a method that
combines PCA and Fisher’s linear discriminant analysis
(FLDA) to determine the best discrimination pattern.16
First, PCA performs dimensional reduction while preserving the variance in the high dimensional image
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space. In the next step, FLDA maximizes the distance
between projected class means while at the same time
minimizing the variance within a class.

PCA
PCA was used to reduce the dimensionality of the data. It
provided a simpliﬁed description of imaging data by projecting the images (consisting of very high-dimensional
vectors) on to the linear space spanned by the eigenvectors of the data covariance matrix.21 We have N number
of PET scans and each scan consists of P number of
voxels constructing a big dimensional space of size
N  P. We performed PCA on this data as follows:
We restructured each image into a one dimensional
vector of size 1  P and then arranged all N images into
a data matrix of N  P dimensions as follows

T
X ¼ xi1 , xi2 , xi3 , . . . , xiN

ð1Þ

where i ¼ 1, 2, 3 , . . . , P
After mean correcting the data X, we used singular
value decomposition (SVD) to obtain a set of basis
vector. The SVD of vector X is given by
1

X ¼ U =2 VT
ð2Þ
P
where
is a diagonal matrix containing the (N – 1)
eigenvalues of X as diagonal elements. U is orthogonal
matrix of size N  (N – 1). VT is an orthogonal matrix
of size (NP
– 1)  P.
U and
can be found by PCA of an N  N matrix
XXT using
XXT ¼ UUT

ð3Þ

VT can be found from the following equation
VT ¼ 

1=
2

UT X

ð4Þ

Finally, the coordinates of the N PET images in the
(N – 1)-dimensional feature space can be represented by
a new matrix Z that is given by
1=

Z ¼ U

2

ð5Þ

Z is a matrix of size N  (N – 1) representing the
reduced dimensional feature space. By substituting the
Z in equation (2), one can return to image space.

Fisher’s linear discriminant analysis
FLDA ﬁnds the optimal direction in the feature space
to classify the data. FLDA is used to classify STN-DBS
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on and oﬀ states using the reduced dimensional space Z,
the product of PCA. Let a be an optimal unit vector in
the feature space that optimally classiﬁes the data. This
vector is known as Fischer’s discriminant vector. Let y
be the projection of Z in the direction of a that is
y ¼ aT Z

ð6Þ

FLDA maximizes a ratio of ‘‘between-class variance’’ to ‘‘within-class variance’’ to reduce the data
variation in the same class and to increase the separation between classes to determine the unit vector a.
This ratio is expressed as
N1 ðm1  mÞ2 þ N2 ðm2  mÞ2
argmaxa ðJa Þ ¼ PN 
2 PN2 
2
1
j¼1 yj  m1 þ
j¼1 yj  m2
ð7Þ
where N1 and N2 are the number of STN-DBS
oﬀ and
P
on images, respectively, and mk ¼ N1k y2Ck y.
After obtaining the optimized direction a in the feature space Z, the discriminating image Ia can be
obtained using the relationship
Ia ¼ Va

ð8Þ

This image Ia presents the spatial pattern that best
separates the two classes (STN-DBS on or oﬀ) in terms
of the FLDA criterion.
To classify a given test image after the training step,
a prediction value was calculated. First we projected a
given test image XT to a feature space using
ZP ¼ XT V

ð9Þ

where ZP was the projection of test image XT to the feature space. The value of the predictor Q was calculated by
using feature vectors corresponding to a number of principal components and the vector a pointing in the direction that maximized the Fischer’s criterion. The
following equation was used to ﬁnd the predictor value.
Q ¼ ZP a

rigid-body alignment was performed on the raw PET
images to correct for head movement. All images were
registered to the ﬁrst image of the series for each subject. Mean images for each subject were estimated and
then nonlinearly normalized to a PET template to
reduce anatomic variability. In order to establish a template for skull-stripping individual PET scans, a mean
image of all 164 scans was created using SPM5 and
templates were manually drawn on the mean image
slices using ‘fslview’ software. All images were skullstripped using SPM5 and the manually generated
template.
We used half (82 out of 164) images for training
purposes and the rest for testing. The training and testing images were randomly selected. A PCA was applied
to the spatially normalized, intra-subject registered, and
skull-stripped images. A total of N – 1 (81) principal
components were calculated.
PCA of the PET images can provide important
information about the underlying covariance structure.
It has been reported in intra-subject and inter-subject
studies that the discriminating pattern is usually contained in the ﬁrst principal component of intra-subject
subspace.22 However, Ardekani et al.16 noted that the
pattern that discriminates between experimental conditions can be spread into several components. We used
PCA to reduce the dimensionality in our data. To
reduce the noise along with the dimensionality, we
selected the ﬁrst 30 components for further analysis.
FLDA was used to discriminate STN-DBS on from
STN-DBS oﬀ scans. The FLDA analysis was repeated
10 times using diﬀerent, randomly selected, training
and testing sets of data. We built in-house software to
implement PCA and FLDA using MATLAB 7.
The accuracy, precision, sensitivity, and speciﬁcity of
the predictions made by FLDA were calculated using
the following equations
Accuracy ¼

TP þ TN
TP þ TN þ FP þ FN

ð11Þ

Precision ¼

TP
TP þ FP

ð12Þ

ð10Þ
Sensitivity ¼

The predictor Q is used to classify the test image.
Details of image processing are presented in the following section.

Image processing
PET images were ﬁrst aligned within subject and then
spatially normalized to a standard space using the
SPM5 software (SPM5, London, UK http://www.ﬁl.
ion.ucl.ac.uk/spm/). In the ﬁrst step, intra-subject

TP
TP þ FN

ð13Þ

TN
TN þ FP

ð14Þ

and
Specificity ¼

where TP, TN, FP and, FN are true positive, true negative, false positive and false negative values,
respectively.

Mubeen et al.
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Table 2. Metrics for the correct classifications of the STN-DBS
state of individual scans.
Analysis
Repetition

Accuracy

Sensitivity

Specificity

Precision

1
2
3
4
5
6
7
8
9
10
Mean

0.8902
0.8171
0.8902
0.8293
0.9512
0.8658
0.8780
0.8049
0.9146
0.8902
0.8732

0.9024
0.8049
0.9512
0.8780
0.9268
0.8293
0.8780
0.7805
0.9024
0.8293
0.8683

0.8780
0.8293
0.8293
0.7805
0.9756
0.9024
0.8780
0.8293
0.9268
0.9512
0.8780

0.8810
0.8250
0.8479
0.8000
0.9744
0.8947
0.8780
0.8205
0.9250
0.9444
0.8791

Note: Accuracy, sensitivity, specificity and precision values of the method
to correctly classify the STN-DBS state of individual scans. Each row
contains the efficacy measure values for each of the 10 ‘‘experiments.’’
The last row shows the mean values of efficacy measures across
‘‘experiments.’’

In order to assess the functional signiﬁcance of the
PCA and PCA-FLDA results, representative measures
were computed to characterize the ﬁrst principal component (PC1) and the FLDA predictor scores. These
two measures were used in correlational analyses with
results of the previously published region-based analyses of global blood ﬂow and with several clinical
measures. The results of the PCA analysis were represented by the magnitude of a feature vector in the direction of ﬁrst principal component (PC1). For the
prediction of DBS-on and oﬀ state using PCA-FLDA,
we utilized the prediction value calculated by equation
(10).

Results
The combination of PCA and FLDA classiﬁed STNDBS on and oﬀ cerebral blood ﬂow images with a high
degree of accuracy and speciﬁcity. To establish the reliability of this method, the analysis was repeated 10
times by randomly choosing training and testing sets
of images. For each repetition, all the eﬃcacy measures
were calculated. The results of these iterations and
mean eﬃcacy values are presented in Table 2. On average, the PCA-FLDA method achieved an accuracy
value of 0.87 with minimum value of 0.80 and a maximum accuracy value of 0.95. Representative composite
images are presented in Figure 1, where the colors represent the direction of the discriminator (i.e. light blue
to dark blue ¼ increasingly negative, red to yellow ¼ increasingly positive). It should be noted that
positive discrimination indicating increased CBF

values are widely distributed across the cerebellum,
but at lower intensity values than are observed in supratentorial brain regions.
To place the present results in context of the previous report of global CBF increases,1 relationships
between several measures derived from the present analyses, the global changes reported previously, and
demographic characteristics were evaluated. STNDBS on – oﬀ diﬀerence scores for global blood ﬂow
were computed from the previously published results,
and these diﬀerence scores were compared across scans
with the ﬁrst principal component score (PC1) as well
as with several derived discriminator scores from the
PCA-FLDA analysis using bivariate correlations. The
PC1 scores for the STN-DBS oﬀ scans were negatively
correlated with the whole brain change scores
[r ¼ 0.264; p ¼ 0.029], indicating that in the oﬀ condition, the on-oﬀ global blood ﬂow scores decreased as
the PC1 oﬀ scores increased. The PC1 scores for the
STN-DBS on scans were positively correlated with the
global change scores [r ¼ 0.512; p < 0.001], indicating
that in the on condition, the on-oﬀ global blood ﬂow
scores increased as the PC1 on scores increased. This is
depicted in Figure 2. Independent of whole brain
change scores, PC1 appears to be a marker of blood
ﬂow, especially in in the DBS on condition. The PC1 on
scores were highly correlated with the region-based
whole brain values in the on condition (r ¼ 0.967;
p < 0.001), and the PC1 oﬀ scores demonstrated a smaller, signiﬁcant correlation with the region-based whole
brain values in the oﬀ condition (r ¼ 0.426; p < 0.001).
Using the PCA-FLDA discriminators, the global diﬀerence scores were negatively correlated with the discriminator scores only in the oﬀ condition [r ¼ 0.25;
p ¼ 0.038].
With respect to subjects’ behavior during scanning,
in the STN-DBS on condition, the PC1 scores were
correlated with pause duration during the speech
tasks [r ¼ 0.436; p ¼ 0.002], similar to the previously
reported relationship with global blood ﬂow changes1
and consistent with the eﬀects of STN-DBS on pausing
during spontaneous speech.23 In this relationship,
global CBF was interpreted as a surrogate marker for
PD severity rather than playing a direct role in motor
speech control.
For clinical variables, the total amplitude of STNDBS electrical stimulation was positively correlated
with PC1 values [r ¼ 0.25; p ¼ 0.025] and the PCAFLDA discriminator scores [r ¼ 0.278; p ¼ 0.012] in
the oﬀ condition. As there was no stimulation in the
oﬀ condition, it appears that total amplitude was serving as a surrogate measure of PD severity. The total
amplitude was also positively correlated with PC1
values in the on condition [r ¼ 0.348; p ¼ 0.001]. For
several other clinical characteristics, signiﬁcant
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Figure 1. Representative brain slices color-coded to represent the results of the PCA-FLDA analysis. The discriminant scores are
superimposed over the average of all 164 PET images. Discrimination pattern coefficients greater than 30% of the maximum absolute
value (approximately two standard deviations from the mean) are shown. Red and blue colors indicate the positive (red to yellow ¼ increasingly positive) and negative (light blue to dark blue ¼ increasingly negative) coefficient values, respectively. One notable
feature is the widespread distribution of positive discrimination values across the cerebellum, but at lower intensity values than in
supratentorial brain regions.

correlations with PC1 and PCA-FLDA scores only
occurred in the STN-DBS oﬀ condition. The duration
of STN-DBS therapy was correlated with the PC1
values [r ¼ 0.335; p ¼ 0.002] and with the PCA-FLDA
discriminator scores [r ¼ 0.289; p ¼ 0.008] in the oﬀ condition. The UPDRS motor scores were also correlated
with the PC1 values [r ¼ 0.35; p ¼ 0.001] and PCAFLDA discriminator scores [r ¼ 0.233; p ¼ 0.035] in
the oﬀ condition. None of these clinical measures
were correlated with the PC1 or PCA-FLDA discriminators scores in the on condition.

Discussion
The results of our voxel-based PCA-FLDA analysis
revealed widespread changes in CBF as a function of
STN-DBS status in individuals with PD. This procedure classiﬁed CBF PET images with respect to STNDBS status during scanning with nearly 90% accuracy
and speciﬁcity. An important point is that this level of
discrimination was conﬁrmed without having to estimate a normalization factor for intersubject global
blood ﬂow for these semi-quantitative CBF measures.
The question of global blood ﬂow normalization has
caused some confusion in the literature on PD imaging,
but it has been shown that network changes in the

Parkinson’s disease related proﬁle (PDRP) are not an
artifact of global changes.24
A comparison between the present and previous
results provides some insights into STN-DBS eﬀects.
The whole-brain CBF on – oﬀ diﬀerence scores previously calculated using regions-of-interest1 were positively correlated with the ﬁrst principal component
values for the STN-DBS on condition and negatively
correlated with the ﬁrst principal component values
for the STN-DBS oﬀ condition. This relationship conﬁrms the previously reported increase in global CBF
during the STN-DBS on condition. However, the
region-based global diﬀerence scores were only correlated with the PCA-FLDA discriminator values calculated for the STN-DBS oﬀ condition. The discrepancy
between the PCA and PCA-FLDA relationships with
whole-brain CBF suggests that while a global increase
in CBF is a signiﬁcant component of the STN-DBS
eﬀect, the accuracy and sensitivity of the PCA-FLDA
are the result of more than just global changes. This
discrepancy, together with the results of the clinical
correlations with the PCA and PCA-FLDA results,
suggests that CBF in the STN-DBS on and oﬀ conditions reﬂect diﬀerent processes to some extent.
While the present study did not examine metabolism, an 18F-ﬂuorodeoxyglucose (FDG) PET study by
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Figure 2. Scatter plots depicting the relationships between the
STN-DBS on – off global CBF values (Sidtis et al.1) and the first
principal component (PC1) values (present study) for the STNDBS on and off conditions. The PC1 scores for the STN-DBS on
scans were positively correlated with the global CBF change
scores [r ¼ 0.512; p < 0.001], indicating that PC1 scores
increased as global CBF blood increased in the on condition. The
opposite relationship between PC1 and global CBF difference
scores [r ¼ 0.264; p ¼ 0.029] was observed in the STN-DBS off
condition.

Garraux et al.10 may be relevant to the present ﬁndings.
Eight PD subjects were studied oﬀ medication in both
STN-DBS on and oﬀ conditions during a resting state.
Absolute quantitative data were not obtained, but
images were normalized using brain areas that did not
change as a function of STN-DBS status. Whole-brain
values were obtained using large regions of interest.
Their analysis indicated that whole-brain FDG
uptake increased by approximately 11% when STNDBS on was compared to oﬀ. Normalizing for these
whole brain diﬀerences, multiple cortical and subcortical areas also increased with STN-DBS on, but no
areas were found to decrease. With respect to regional
changes associated with STN-DBS, Garraux et al.
pointed out that the published results are inconsistent,
with one likely cause being diﬀerences in the ways in
which regional data were normalized for global eﬀects.
The range of sometimes conﬂicting regional changes
associated with STN-DBS is reviewed by Garraux
et al. so they will not be revisited in this paper.
The relationships between cerebral glucose metabolism and CBF following levodopa administration or
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STN-DBS treatment were examined by Hirano
et al.25 A voxel-based pattern analysis revealed
increased CBF but decreased glucose metabolism with
the administration of levodopa in a previously established PD related network (PDRP). Similar local dissociations were noted in multiple brain areas using a
regional approach. The dissociation between CBF and
glucose metabolism with the administration of levodopa was not observed during STN-DBS.
Although not explicitly addressing the question of
whole-brain CBF changes with STN-DBS, two single
photon emission-computed tomography (SPECT) studies revealed bilateral, large, multi-region CBF
increases. Sestini et al.26 studied 10 PD subjects, oﬀ
medication, at rest. They did not evaluate possible
whole-brain CBF changes, instead scaling all of the
scans across conditions to a common global value
(50 mL/100 mL per minute). Nevertheless, they found
widespread bilateral increases in CBF when STNDBS on values were compared to pre-operative and
STN-DBS oﬀ conditions. Nagai et al.27 studied a
large group of STN-DBS subjects (N ¼ 92) with
SPECT. The subjects were divided into groups based
on their UPDRS part III scores oﬀ medication. Wholebrain changes were not explicitly considered in their
analysis either, but as in the Sestini et al.26 study,
widespread bilateral CBF increases were reported
after STN-DBS, with the largest increases found in
the subgroup with the best clinical outcome. In both
SPECT studies, the DBS eﬀects on CBF were anatomically extensive.
While the studies that address whole-brain changes
with STN-DBS are limited, the available evidence suggests that such changes are neurophysiologically meaningful. Just as the therapeutic mechanisms of STN-DBS
remains unclear, so are the mechanisms of STN-DBS
global CBF changes. Leenders et al.28 examined the
question of whether the increased CBF following
administration of levodopa was related to increased
oxygen metabolism. Using 15O PET, they measured
CBF and oxygen metabolism in PD and normal subjects. Glucose metabolism was not measured. Both participant groups demonstrated increased CBF but no
increase in oxygen metabolism, suggesting that the
levodopa-induced CBF increases were not driven by
changes in oxidative metabolism. In the PD group,
CBF increased by 13% in the cortex and 20% in the
basal ganglia, with smaller increases in the non-PD control group. Leenders et al. argued that these results
were consistent with the available human and animal
evidence indicating that stimulation of the dopaminergic system with dopaminergic agonists or levodopa
increased CBF. As levodopa is a vasoactive substance
that is associated with both vasoconstriction and vasodilation,29–32 it appears that the dopaminergic system
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could be a candidate for a role in whole-brain CBF
changes during STN-DBS.
Stimulation of astrocytes during STN-DBS is
another possible mechanism for global CBF
changes.7–9 Astrocytes play a signiﬁcant role in the
regulation of CBF, especially at the microvascular
level, and may regulate CBF independent of metabolic
demand.33–35 The involvement of astrocytes in the eﬀect
of STN-DBS on CBF provides a mechanism for widespread brain changes and expands the palate of potential vasoactive substances beyond levodopa.
The present study suggests that STN-DBS produces a global increase in CBF, as reﬂected in the
PC1 measure, as well as local or regional changes
and network alterations, as inferred but not identiﬁed
by the PCA-FLDA measures and the existing literature. Network changes do occur in these data, however, as we have identiﬁed functionally signiﬁcant
speech-speciﬁc cortical-subcortical changes independent of the global CBF eﬀect.36 The results of this
study, together with the existing literature, raise several important questions. Does STN-DBS alter functional hyperemia and cerebral autoregulation? In this
study, the discriminators derived from the PCA and
the PCA-FLDA analyses were correlated to clinical
measures in the STN-DBS oﬀ condition, but not the
on condition. This dissociation may reﬂect the observation by Leenders et al.28 that CBF increases following levodopa administration were not associated
with corresponding changes in oxidative metabolism.
The relationships between CBF and glucose metabolism appear to be diﬀerent.25

Conclusions
STN-DBS is a clinically eﬀective tool in the treatment
of PD, but the therapeutic mechanisms remain
unknown. We have previously reported signiﬁcant
increases in global CBF with STN-DBS in the on
state, and the present PCA results support that observation. However, the high accuracy and speciﬁcity of
the PCA-FLDA method in discriminating on and oﬀ
conditions, while not completely capturing the wholebrain CBF increases, indicate that STN-DBS eﬀects are
more than global. Further, the observations that the
CBF measures derived from the PCA-FLDA analysis
were correlated with clinical measures in the STN-DBS
oﬀ condition but not the on condition suggests some
degree of dissociation between STN-DBS CBF
increases and normal cerebrovascular principals like
functional hyperemia and cerebral autoregulation.
The identiﬁcation of both global and local CBF
changes associated with STN-DBS suggests a broader,
albeit more complicated, approach to understanding its
therapeutic mechanisms. The eﬀects of STN-DBS will
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likely require characterizations in regional, network,
and global domains.
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